A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06356571 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Plasma Cell Myeloma Refractory

Interventions

DRUG: Isatuximab SC-OBDS
DRUG: Montelukast
DRUG: Dexamethasone
DRUG: Acetaminophen
DRUG: Diphenhydramine
DRUG: Methylprednisolone
DRUG: Carfilzomib

Sponsor

Sanofi